Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy

  title={Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy},
  author={A. Lansiaux and S. Salingue and Am{\'e}lie Dewitte and S. Clisant and N. Penel},
  journal={Investigational New Drugs},
SummarySeveral previous reports suggest that thrombospondin (TSP-1) may be a mediator of the antiangiogenic effects of low-dose metronomic cyclophosphamide-based chemotherapy (MC). We conducted a randomized phase II trial evaluating megestrol acetate (n = 44) versus MC (n = 44) in patients having exhausted all standard treatments. We measured the TSP-1 levels at baseline and D15. We did not observe significant differences in TSP-1 at baseline in the two arms (p = 0.07). TSP-1 levels decreased… Expand
Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients†
TSP-1 and VEGF levels were significantly lower and higher in cancer patients than in healthy dogs, but they were not influenced by any of the studied metronomic treatment regimens. Expand
Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
It is difficult to objectively evaluate the additional value of the metronomic administration of cyclophosphamide, and further clinical trials integrating translational research are necessary to better evaluate the clinical benefit of this promising approach. Expand
A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.
This work searched the MEDLINE, EMBASE, CENTRAL and PubMed databases for correlative studies conducted as part of LDM chemotherapy trials in order to identify the most promising biomarker candidates and found angiogenesis-related biomarkers were most commonly studied. Expand
Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors
The combination of oral sirolimus, topotecan, and cyclophosphamide was well tolerated and biomarker studies demonstrated modulation of angiogenic pathways with this regimen. Expand
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.
MCT with cyclophosphamide plus celecoxib is safe and shows a therapeutic effect in advanced breast cancer patients and Evaluation of patients' quality of life showed no changes during the response period. Expand
Preclinical Evaluation of Oral Metronomic Topotecan and Pazopanib for the Treatment of Aggressive Extracranial Pediatric Solid Tumors
  • S. Kumar, G. Zadeh
  • Medicine
  • Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 2014
In vivo, the combination of topotecan and pazopanib demonstrated significant anti-tumor activity compared to the respective single agents, and the mechanisms of resistance to the therapy were studied. Expand
Conventional chemotherapy is given once in every three weeks or two weeks at maximum tolerated dose. Drug-free interval is given to allow normal proliferating cells to recover. MetronomicExpand
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
The most important studies that have analyzed metronomic chemotherapy processes, including activation of immunity, induction of tumor dormancy, chemotherapy-driven dependency of cancer cells, and the '4D effect are reported. Expand
Pharmacokinetics and Pharmacogenetics of Metronomics
Trials integrating pharmacokinetic and pharmacogenetics research are necessary to better evaluate the clinical benefit of metronomic chemotherapy and represent a mandatory step to treatment personalization. Expand
Efficacy of metronomic chemotherapy with oral cyclophosphamide and methotrexate in patients with non-Hodgkin lymphoma: A retrospective analysis
It is concluded that metronomic therapy with an oral CM regimen administered for continuous, prolonged periods represents a well-tolerated treatment for recurrent NHL, especially in elderly patients. Expand


Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
The results implicate TSP-1 as a secondary mediator of the antiangiogenic effects of at least some low-dose metronomic chemotherapy regimens, suggesting a marked and selective sensitivity of activated endothelial cells. Expand
Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
Metronomic cyclophosphamide is well tolerated and provides stable disease in such vulnerable and poor-prognosis cancer patients and warrants further evaluations. Expand
The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin
Systemic low-dose continuous treatment of a rat prostate cancer model with cyclophosphamide and paclitaxel induced the expression of TSP in tumour tissue and inhibited tumour growth, supporting the hypothesis that the anti-tumour effect of low- dose metronomic chemotherapy, at least with certain chemotherapeutics, is partly mediated by induction of endogenous antiangiogenic factors. Expand
High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
The decline in circulating endothelial cells and their precursors suggests that this combination of low-dose cyclophosphamide and high-dose celecoxib is working by inhibiting angiogenesis but should be validated in a larger patient sample. Expand
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic.
Many cancers are intrinsically resistant to chemotherapy and most of the remainder, which are initially responsive, usually acquire resistance afterwards, so the hypothetical beneficial anti-angiogenic side effect of chemo-therapy would seem negligible, or minimal, at best. Expand